11.01.24 Master complaint filed in Pennsylvania Patients who used Ozempic filed a master complaint in the sprawling multidistrict litigation centralized in the Eastern District of Pennsylvania
The immunohistochemistry markers with positive results were: HMB45, cytoplasmic marker, marking melanocytes (Figure 2C), protein S100, cytoplasmic marker, melanocytic (Figure 2D), CD99 membrane marker, marking neuroblastic cells (Figure 2E) and enolase (NSE), cytoplasmic marker, neuroectodermal (Figure 2F), which were monitored
No pressure, just honest recommendations
Advantages of BPC-157: Broader preclinical evidence base across multiple organ systems
Nerve-related pain may improve through neuroprotective mechanisms